NEW YORK (GenomeWeb) – GenomeDx announced today an expansion of its research agreement with the Mayo Clinic to start a validation study for the expanded use of GenomeDx's Decipher Prostate Cancer Classifier.
GenomeDx will have continued access to clinical data from Mayo's cohort of prostate cancer samples, enabling the San Diego-based firm to conduct longer-term follow-up and evaluation of biomarkers. The partners began collaborating in 2009, and in 2013 they expanded their deal to include an exclusive license to certain co-developed and Mayo-developed intellectual property.
The Decipher test analyzes whole genomes to profile RNA expression signatures. It measures the aggressiveness of prostate cancer in patients who have had a prostatectomy and classifies a patient's risk of disease progression, metastasis, and prostate-related death after a prostatectomy.